▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #830 by analyst upside · 2026-08-13
RARE
Ultragenyx Pharmaceutical Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+96.7%
implied upside to consensus target
Current Price $26.86
Consensus Target $52.84
Bull Target $96.0
Bear Target $27.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
12
Hold
2
Sell
0
52-Week Low $18.29
52-Week High $39.89
YTD Return +13.8%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 10.2x
EPS (TTM) $-5.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $717M
Profit Margin -81.7%
52-WEEK RANGE
52-Week Low $18.29
52-Week High $39.89
Current Price $26.86
Bear Target $27.0
Bull Target $96.0
● Now $26.86 ● Target $52.84
TRADING DATA
Avg Volume 2.3M
YTD Return +13.8%
Analyst Count 19
Consensus Buy
Upside to Target +96.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Ultragenyx Pharmaceutical Inc. (RARE) is currently trading at $26.86 with a Wall Street consensus price target of $52.84, implying potential upside of 96.7% over the next 12 months. 19 analysts currently cover RARE, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $96.0, while the most cautious has a target of $27.0.

RARE operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 13.8% year-to-date and is currently trading near the lower end of its 52-week range of $18.29 – $39.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +73.8%
ADMA Biologics, Inc.
$2B · P/E 14.2x · Buy
GTBIF +124.1%
Green Thumb Industries Inc.
$2B · P/E 13.5x · Buy
INVA +68.2%
Innoviva, Inc.
$2B · P/E 4.8x · Buy
ANIP +44.3%
ANI Pharmaceuticals, Inc.
$2B · P/E 16.4x · Buy
HRMY +15.9%
Harmony Biosciences Holdings, Inc.
$2B · P/E 12.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for RARE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald reit
Overweight → Overweight 2024-10-22 40% win rate (10 calls)
TD Cowen - Reiterated
Buy → Buy 2024-10-21 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-10-01 40% win rate (10 calls)
RBC Capital reit
Outperform → Outperform 2024-09-26 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-20 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-16 40% win rate (10 calls)
Barclays - Reiterated
Overweight → Overweight 2024-08-05 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2024-08-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →